Comparative analysis of two novel complete genomes of myxoma virus vaccine strains.
Poxvirus
Myxoma virus
Rabbits
Vaccine
Whole-genome sequencing
Journal
Virus genes
ISSN: 1572-994X
Titre abrégé: Virus Genes
Pays: United States
ID NLM: 8803967
Informations de publication
Date de publication:
11 Jul 2024
11 Jul 2024
Historique:
received:
22
02
2024
accepted:
05
07
2024
medline:
11
7
2024
pubmed:
11
7
2024
entrez:
11
7
2024
Statut:
aheadofprint
Résumé
Myxoma virus (MYXV) is a double-stranded DNA-containing virus of the family Poxviridae, genus Leporipoxvirus. MYXV is an important model virus for evolutionary and immunological research and a promising oncolytic. In this study, we sequenced and analyzed two complete genomes of MYXV virus vaccine strains B-82 and Rabbivac-B, which are widely used for vaccine production in Russia. Here, we first show that MYXV vaccine strains B-82 and Rabbivac-B share a common origin with the American recombinant MYXV MAV vaccine strain. In addition, our data suggest that the MYXV B-82 and Rabbivac-B strains contain a number of genes at the 5' and 3' ends that are identical to the virulent MYXV Lausanne strain. Several unique genetic signatures were identified in the M013L, M017L, M023, and M121R genes, helping to achieve high genetic resolution between vaccine strains. Overall, these findings highlight the evolutionary flexibility of certain genes in the MYXV genome and provide insights into the molecular epidemiology of the virus and subsequent vaccine development.
Identifiants
pubmed: 38990486
doi: 10.1007/s11262-024-02090-7
pii: 10.1007/s11262-024-02090-7
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Ministry of Science and Higher Education of the Russian Federation
ID : Priority-2030
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Kerr PJ et al (2015) Myxoma virus and the Leporipoxviruses: an evolutionary paradigm. Viruses 7:1020–1061
doi: 10.3390/v7031020
pubmed: 25757062
pmcid: 4379559
Braun C et al (2017) Genetic variability of myxoma virus genomes. J Virol. https://doi.org/10.1128/JVI.01570-16
doi: 10.1128/JVI.01570-16
pubmed: 27903800
pmcid: 5286896
Spiesschaert B, McFadden G, Hermans K, Nauwynck H, Van de Walle GR (2011) The current status and future directions of myxoma virus, a master in immune evasion. Vet Res 42:1–18
doi: 10.1186/1297-9716-42-76
Kerr PJ et al (2019) Punctuated evolution of myxoma virus: rapid and disjunct evolution of a recent viral lineage in Australia. J Virol. https://doi.org/10.1128/jvi.01994-18
doi: 10.1128/jvi.01994-18
pubmed: 30728252
pmcid: 6450118
Kerr PJ et al (2013) Comparative analysis of the complete genome sequence of the California MSW strain of myxoma virus reveals potential host adaptations. J Virol 87:12080–12089
doi: 10.1128/JVI.01923-13
pubmed: 23986601
pmcid: 3807925
Kerr PJ et al (2012) Evolutionary history and attenuation of myxoma virus on two continents. PLoS Pathog 8:e1002950
doi: 10.1371/journal.ppat.1002950
pubmed: 23055928
pmcid: 3464225
Cavadini P, Botti G, Barbieri I, Lavazza A, Capucci L (2010) Molecular characterization of SG33 and Borghi vaccines used against myxomatosis. Vaccine 28:5414–5420
doi: 10.1016/j.vaccine.2010.06.017
pubmed: 20598407
Jackson RJ, Hall DF, Kerr PJ (1999) Myxoma virus encodes an alpha2,3-sialyltransferase that enhances virulence. J Virol 73:2376–2384
doi: 10.1128/JVI.73.3.2376-2384.1999
pubmed: 9971821
pmcid: 104483
Rahman MM, McFadden G (2020) Oncolytic virotherapy with myxoma virus. J Clin Med Res 9:171
Jin K-T et al (2021) Oncolytic virotherapy in solid tumors: the challenges and achievements. Cancers 13:588
doi: 10.3390/cancers13040588
pubmed: 33546172
pmcid: 7913179
Gunenkov VV, Chistova ZYa, Kuznetsova GD, Nochevniy VT, Safonov GA, Kalinina TA, Karpov VM Russian patent №1169221. Virusvaktsina protiv miksomatoza krolikov i sposob yeye izgotovleniya [in Russian] filled 23.12.1983 and issued 10.10.1995
Sereda AD, Kolosova MV, Zhesterev VI, Lunitsin AV, Yurkov SG, Natashkina MYu, Repin VI, Malogolovkina NV, Bobrovskaya NK. Russian patent №2255764. Sposob izgotovleniya vaktsiny protiv miksomatoza krolikov [in Russian]. filled13.03.2003 and issued 24.12.2004
Lapteva OG, Yurkov SG, Sindryakova IP, Lunitsin AV (2021) Comparative characterization of Leporipoxvirus members’ reproduction in continuous cell culture. Veterinary Science Today 10(4):323–328. https://doi.org/10.29326/2304-196X-2021-10-4-323-328
doi: 10.29326/2304-196X-2021-10-4-323-328
van Vloten JP et al (2021) Production and purification of high-titer OrfV for preclinical studies in vaccinology and cancer therapy. Mol Ther Methods Clin Dev 23:434–447
doi: 10.1016/j.omtm.2021.08.004
pubmed: 34786436
pmcid: 8579082
Bankevich A et al (2012) SPAdes: a new genome assembly algorithm and its applications to single-cell sequencing. J Comput Biol 19:455–477
doi: 10.1089/cmb.2012.0021
pubmed: 22506599
pmcid: 3342519
Martin DP, Murrell B, Golden M, Khoosal A, Muhire B (2015) RDP4: Detection and analysis of recombination patterns in virus genomes. Virus Evol 1:vev003
doi: 10.1093/ve/vev003
pubmed: 27774277
pmcid: 5014473
Tamura K, Stecher G, Kumar S (2021) MEGA 11: molecular evolutionary genetics analysis version 11. Mol Biol Evol. https://doi.org/10.1093/molbev/msab120
doi: 10.1093/molbev/msab120
pubmed: 33892491
pmcid: 8233496
Dos Santos FAA et al (2022) Evaluation of commercial myxomatosis vaccines against recombinant myxoma virus (ha-MYXV) in Iberian hare and wild rabbit. Vaccines 10:356
doi: 10.3390/vaccines10030356
Huson DH, Bryant D (2006) Application of phylogenetic networks in evolutionary studies. Mol Biol Evol 23:254–267
doi: 10.1093/molbev/msj030
pubmed: 16221896